Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study on Concurrent Cisplatin-based Chemotherapy Combined With Vaccination Therapy With the P16_37-63 Peptide in Patients With HPV- and p16INK4a-positive Cancer

NCT02526316 is registered in ClinicalTrials.gov with Oryx GmbH & Co. KG as lead sponsor.

NCT NCT02526316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02526316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study on Concurrent Cisplatin-based Chemotherapy Combined With Vaccination Therapy With the P16_37-63 Peptide in Patients With HPV- and p16INK4a-positive Cancer
Lead sponsor
Oryx GmbH & Co. KG
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2015
Completion date
May 31, 2017
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-induced cancers